APA (7th ed.) Citation

Borchmann, P., & Meißner, J. (2017). Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): An open-label, international, randomised phase 3 study by the German Hodgkin Study Group. The lancet. Oncology, 18(4), . https://doi.org/10.1016/S1470-2045(17)30103-1

Chicago Style (17th ed.) Citation

Borchmann, Peter, and Julia Meißner. "Progression-free Survival of Early Interim PET-positive Patients with Advanced Stage Hodgkin's Lymphoma Treated with BEACOPP Escalated Alone or in Combination with Rituximab (HD18): An Open-label, International, Randomised Phase 3 Study by the German Hodgkin Study Group." The Lancet. Oncology 18, no. 4 (2017). https://doi.org/10.1016/S1470-2045(17)30103-1.

MLA (9th ed.) Citation

Borchmann, Peter, and Julia Meißner. "Progression-free Survival of Early Interim PET-positive Patients with Advanced Stage Hodgkin's Lymphoma Treated with BEACOPP Escalated Alone or in Combination with Rituximab (HD18): An Open-label, International, Randomised Phase 3 Study by the German Hodgkin Study Group." The Lancet. Oncology, vol. 18, no. 4, 2017, https://doi.org/10.1016/S1470-2045(17)30103-1.